What Japanese specialists warned about Mounjaro side effects
Japanese obesity specialists have warned against using medicines such as Mounjaro alongside severe food restriction to achieve rapid weight loss, according to Seoul Economic Daily reporting published on 4 October 2026. The warning in Japan concerns potentially serious metabolic complications and use for cosmetic purposes among people without obesity or diabetes.
The Japan Society for the Study of Obesity said that sharply reducing food intake while taking these medicines can allow ketones, produced as the body breaks down fat, to accumulate excessively. Symptoms can include vomiting, abdominal pain and profound tiredness, the newspaper reported, citing NHK and Kyodo News.
If the condition progresses to ketoacidosis, the blood becomes too acidic. Severe cases can involve dehydration and impaired consciousness and require emergency treatment. The concern is not simply how much weight someone loses, but the combination of medication, inadequate nutrition and rapid loss.
The report also gave figures for suspected adverse reactions submitted to Japan’s Pharmaceuticals and Medical Devices Agency. About 950 Mounjaro-related reports were recorded between 2023 and 22 September 2026; 35 involved use outside the intended indication, including dieting or cosmetic treatment.
Those figures are reports of suspected harm, not proof that Mounjaro caused every event. Without the number of people treated, they cannot establish how frequently side effects occur, or whether the risk differs between approved and unapproved uses. The 35 reports should not be read as 35 confirmed cases of ketoacidosis: the account does not provide that breakdown.
How Mounjaro’s Japanese approval differs from UK treatment
Mounjaro contains tirzepatide, a weekly injectable medicine that acts on GIP and GLP-1 receptors involved in blood-sugar regulation and appetite. Although often discussed alongside GLP-1 medicines, it acts on both pathways.
In Japan, Mounjaro is authorised for type 2 diabetes. Tirzepatide is separately licensed for obesity under the brand name Zepbound. The distinction matters: the warning does not mean that the active ingredient has no approved role in weight management, but that the brand, indication and conditions of treatment must be considered together.
An explainer published on the Japanese platform note dates Zepbound’s Japanese approval to December 2024 and its launch to April 2025. Drawing on government insurance documents, it describes eligibility rules based on body mass index and associated illness, alongside requirements for previous treatment and clinical supervision.
According to that account, insured treatment requires an inadequate response to at least six months of diet and exercise therapy, with regular nutritional guidance. It also describes specialist-provider requirements, monthly monitoring and stopping rules where improvement is insufficient. These are Japanese reimbursement conditions, not instructions for patients elsewhere.
Some Japanese institutions offer Mounjaro for cosmetic or weight-loss purposes through self-funded care outside health insurance, Seoul Economic Daily reported. Paying privately does not itself establish whether treatment is appropriate, and a prescription does not remove the need to assess the patient’s health, nutritional intake and reasons for seeking treatment.
The UK position is different. Mounjaro is authorised for weight management in eligible adults as well as for type 2 diabetes. NHS access is subject to eligibility rules and service arrangements; a Japanese warning about use outside local approval should not be mistaken for a withdrawal of the UK weight-management indication.
Nausea, vomiting, diarrhoea and constipation are recognised gastrointestinal side effects of tirzepatide. The Japanese warning draws attention to an additional clinical concern when appetite suppression is accompanied by excessive restriction of food, rather than showing that every person with digestive symptoms has dangerous ketone levels.
What Japanese authorities and Eli Lilly have said
The obesity society said people without obesity or diabetes who take these medicines for appearance-related reasons may face risks that have not been adequately examined in clinical trials, according to Seoul Economic Daily. Evidence from patients with a medical indication cannot automatically establish the balance of benefit and harm in people outside those groups.
Japan’s Ministry of Health, Labour and Welfare has separately cautioned against treating these prescription medicines as casual slimming products. The newspaper reported the ministry’s warning that safety and effectiveness are not established for some cosmetic or dieting uses and that unexpected harm may occur.
The note explainer also reports that Eli Lilly Japan issued an appropriate-use warning in June, and that the ministry notified medical institutions on 16 June. Its account identifies low blood sugar, acute pancreatitis and vomiting among the adverse effects highlighted. These earlier communications place the society’s intervention within a continuing effort to improve prescribing practice.
The ministry has also warned that person-to-person pharmaceutical sales through social media and online secondhand marketplaces are illegal in Japan. According to Seoul Economic Daily, products sold this way may be counterfeit, degraded or of uncertain composition. That creates a separate risk from the known adverse effects of an authentic medicine supplied through a legitimate clinical service.
In Britain, scrutiny of how patients encounter these treatments has focused in part on promotion, including complaints over weight-loss drug advertising. Advertising oversight and clinical safety warnings address different responsibilities: one concerns how demand is generated, the other whether treatment is suitable and properly supervised.
What happens next for Mounjaro prescribing in Japan
The note account dates the society’s statement to an academic meeting in Utsunomiya on 3 October. It said the full text was expected on the society’s website but had not been published when the explainer was written. The supplied reporting therefore does not establish the complete wording or any additional recommendations it may contain.
Neither account reports a new prohibition on approved obesity treatment or a withdrawal of Mounjaro’s diabetes licence. The immediate issue is how prescribers apply existing indications and safeguards, particularly in self-funded services offering treatment for weight loss.
There is also a financial consequence for patients who suffer serious harm. Japan’s adverse-drug-reaction relief scheme generally covers eligible injuries arising despite appropriate use. The ministry warned that people using these medicines for unapproved cosmetic or dieting purposes are unlikely to qualify, according to Seoul Economic Daily; this concerns Japan’s scheme, not UK compensation arrangements.
Follow-up after treatment remains another clinical consideration. Research has documented weight regain after tirzepatide withdrawal, while separate work is examining whether structured support can limit regain after weight-loss injections stop. An intended short course therefore needs an assessment of what follows, as well as whether starting treatment is justified.
Important questions remain unanswered by the reported safety figures: which reactions occurred, how severe they were, what doses were used and how much patients were eating. Those details would be needed to assess the pattern of harm more precisely. The available evidence supports caution about severe restriction and unsupervised supply, not a numerical estimate of an individual patient’s risk.
